1998-2002 MD, University of Vermont College of Medicine, Burlington, VT
1996-1998 MPH, Boston University School of Public Health, Boston, MA. Thesis: The Structure, Organization, and Core Functions of Local and Municipal Public Health
1996-1998 MA, Medical Sciences, Boston University School of Medicine, Boston, MA
1992-1996 AB, Biology, History, Washington University, St. Louis, MO
Hospital Medicine, medical students and resident teaching
Preventative medicine, vaccines, challenge models
2015-present Associate Professor, Department of Medicine, University of Vermont College of Medicine, Burlington, VT
2007-2015 Assistant Professor, Department of Medicine, University of Vermont College of Medicine, Burlington, VT
2005-2006 Chief Resident and Clinical Instructor, Department of Medicine, University of Vermont College of Medicine, Burlington, VT
2014 Scientific Advisory Board, PATH
2006-Present Attending Physician, Primary Care Internal MedicineUniversity of Vermont Medical Center (formerly Fletcher Allen Health Care), Burlington, VT
2007-2009 American Board of Internal Medicine
Principal Investigator (2015-Present) Develop and implement a complex inpatient clinical trial of Cryptosporidium infection based on a human challenge model, which is needed to advance development of therapeutics against Cryptosporidium.
Co-Investigator. (2014) National Institutes of Health and Johns Hopkins Bloomberg School of Public Health. Clinical trials investigating the safety and immunogenicity of candidate vaccine against West Nile Virus. Funded.
Site Co-Principal Investigator. (2014) PaxVax. A Phase III randomized, double-blind, placebo-controlled study in older adults to assess immunogenicity and clinical acceptability of a single-dose of the live oral cholera vaccine candidate PXVX0200 Vibrio cholera 01 Serotype Inaba Vaccine strain CVD103-HgR. Funded.
Site Co-Principal Investigator. (2013-2015) PaxVax. A Phase III Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose of Live Oral Cholera Vaccine Candidate, PXVX0200 CVD 103-HgR Strain, in Preventing Cholera following Challenge with Vibrio cholerae O1 El Tor Inaba 10 Days or 3 Months after Vaccination. Funded.
Investigator. (2012-Present) Inpatient management of venous thromboembolism: Evaluation of clinician adherence to FAHC guidelines and creation of an order set to standardize treatment. Unfunded.
Investigator. (2009-2010) Navy Medical Research Center. Homologous Protection due to Campylobacter jejuni. Funded.
Co-Investigator. (2009-2019) National Institutes of Health (A02008011) and Johns Hopkins Bloomberg School of Public Health. Phase I and II clinical trials investigating safety and immunogenicity of candidate monovalent and tetravalent dengue vaccines. Funded.
Co-Investigator. (2008) Emergent Biosciences. A double-blinded, placebo controlled trial of a single-oral dose typhoid vaccine, MS01.13. Funded.
Co-Investigator. (2007) ACE Biosciences. A Challenge Model of Campylobacter jejuni infection. Funded.
2004 Case Vignette Winner: “Not your typical myocardial infarction: A case of Tako-tsubo cardiomyopathy”,New Hampshire/Vermont Annual ACP Meeting, Stowe, VT
1999 Outstanding Student Presentation: “Are women over fifty, who have recently fractured a bone, receiving information about osteoporosis?” Innovations and Research in Primary Care XIII, Burlington, VT
B Kirkpatrick, A Durbin, K Pierce, M Carmolli, C Tibery, P Grier, N Hynes, S Diehl, D Elwood, A Jarvis, B Sabundayo, C Lyon, C Larsson, M Jo, J Lovchik, C Luke, MC Walsh, E Fraser, K Subbarao, S Whitehead. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naïve Adults. Journal of Infectious Diseases 2015:212: 702-10.
Kirkpatrick BD, Lyon CE, Porter CK, Maue C, Guerry P, Pierce KK, Carmolli MP, Riddle MS, Larsson CJ, Hawk D, Dill EA, Poly F, Fimlaid KA, Hoq F, Tribble DR. Lack of Homologous Protection against Campylobacter jejuni CG8421 in a Human Challenge Model. Clinical Infectious Diseases 2013; 57(8): 1106-13.
CE Lyon, KS Sadigh, MP Carmolli, C Harro, E Sheldon, JC Lindow, CJ Larsson, T Martinez, A Feller, CH Ventrone, DA Sack, B DeNearing, A Fingar, K Pierce, EA Dill, HI Schwartz, EE Beardsworth, B Kilonzo, JP May, W Lam, A Upton, R Budhram, BD Kirkpatrick. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 1010 colony-forming units. Vaccine 2010; 28: 3602-8.
Tribble D, Baqar S, Carmolli M, Porter C, Pierce K, Sadigh K, Guerry P, Larsson CJ, Rockabrand D, Ventone C, Poly F, Lyon C, Dakdouk S, Fingar A, Gilliland Jr. T, Daunais P, Jones E, Rymarchyk S, Huston C, Darsley M, Kirkpatrick BD. Campylobacter jejuni strain CG8421: A refined model for the study of campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. Clinical Infectious Diseases 2009; 49: 1512-19.
Fan S, Lyon C, Savage P, Ozonoff A, Ades PA, Balady GJ. Outcomes and Adverse Events Among Patients with Implantable Cardiac Defibrillators in Cardiac Rehabilitation: A Case-Controlled Study. J Cardiopulm Rehabil Prev 2009; 29(1): 40-43.
Ades P, Savage P, Brawner C, Lyon C, Ehrman J, Bunn J, Keteyian S. Aerobic Capacity in Patients Entering Cardiac Rehabilitation. Circulation 2006; 113(23): 2706-12.